论文部分内容阅读
目的 探讨舒肝解郁胶囊与舍曲林治疗抑郁症的疗效及对超敏c反应蛋白的影响.方法 将96例轻、中度抑郁症患者采用随机数字表法分为两组,舒肝解郁组46例,舍曲林组50例,将40名健康者设为对照组.比较两组临床疗效,不良反应发生率,比较治疗前后两组汉密顿抑郁量表评分及超敏c反应蛋白水平.结果 两组临床疗效比较差异无统计学意义(P＞0.05),舒肝解郁组不良反应发生率显著低于舍曲林组(P＜0.05).治疗2周末起两组汉密顿抑郁量表评分均较治疗前显著降低(P＜0.01),治疗前及治疗后各时点两组评分比较差异无统计学意义(P＞0.05).治疗前及治疗2周末舒肝解郁组与舍曲林组超敏c反应蛋白水平均显著高于对照组(P＜0.05),治疗4周末起两组均显著降低,与对照组比较差异无统计学意义(P＞0.05).结论 舒肝解郁胶囊及舍曲林治疗抑郁症疗效均较好,均能显著降低患者的超敏C反应蛋白水平,但舒肝解郁胶囊安全性更高,值得临床推广应用.“,”Objective To observe the effect of Shuganjieyu capsules and sertraline in treatment of depression and the influence on hs-CRP level. Method A total of 96 patients with mild to moderate depression were randomly divided into 2 groups, 46 cases in Shuganjieyu group.50 cases in sertraline group, 40 healthy people were selected as the control group. Compare the clinical effect, adverse reaction rate, HAMD score and hs-CRP level before and after treatment of the two groups. Result There was no statistic significance in the clinical effect between the two groups (P＞0.05), adverse reaction rate of the Shuganjieyu group was significantly lower than that of the sertraline group(P＜0.05). At the end of 2 weeks after treatment, the HAMD scores of the two groups were significantly declined (P＜0.01), there was no statistic significance between the two groups before treatment and each time point after treatment (P＞0.05). Before treatment and at the end of 2 weeks after treatment, hs-CRP levels of the Shuganjieyu group and sertraline group were all significantly higher than those of the control group (P＜0.05),at the end of 4 weeks after treatment, the two groups were all significantly declined, the difference was not statistically significant compared with the control group (P＞0.05). Conclusion Shuganjieyu capsules and sertraline have better clinical effect in treatment of depression, they can all significantly lower the hs-CRP level, but the former has higher safety, which is worthy of clinical application.